Navigation Links
2013 Pharmaceutical Drug Naming Trends
Date:5/2/2013

NEW YORK, May 2, 2013 /PRNewswire-iReach/ -- For the first quarter of the 2013 calendar year, the FDA's Center for Drug Evaluation and Research (CDER) has approved nine new molecular entities. A total of 39 novel new medicines were approved in 2012, the highest total in sixteen years. Our conclusions are based on a comparison of the average number of letters and syllables in tandem with POCA (Phonological Orthographic Computer Analysis) for the combined proprietary drug names approved in 2012 and 2013. Two of the approved NME's in 2012, choline C-11 and raxibacumab, were approved with the non-proprietary name in place of a proprietary name. The average for both number of letters and number of syllables has increased in the first quarter of 2013. The average number of letters increased from 7.2 to 7.7. The average number of syllables increased from 2.9 to 3.2.

(Photo: http://photos.prnewswire.com/prnh/20130502/CG05717)

The comparison of POCA ratings includes a merged (M) average of the distinct orthographic (O) and phonetic (P) ALINE algorithms as well as the individual similarity ratings derived from all drug products listed within the Orange Book (as of April 16th, 2013). Although the average percentage of similarity for the most similar names remained consistent at 62% (merged) and 63% (orthographic) from 2012 to 2013, the phonetic average for the most similar names increased in 2013. For 2013 Q1 approvals, we note that the number of names where similarity is greater or equal to 60% is in decline based on the merged and orthographic similarity measures.

While it remains early in the calendar year of 2013, the trend to create names which can establish points of difference related to the number and type of letters, i.e., ascending and descending letter characteristics, is logical in the context of known FDA Division of Medication Error Pr
'/>"/>

SOURCE Brandpersand
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. SynteractHCR Addressing Successful Ways to Approach Sponsor and CRO Collaboration at May Pharmaceutical Events in US and Europe
2. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
3. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
4. AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
5. Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results
6. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
7. Paratek Pharmaceuticals Announces Expanded FDA Grant of Qualified Infectious Disease Product (QIDP) Designation for Its Lead Product Candidate, Omadacycline
8. GW Pharmaceuticals Announces Pricing of Initial Public Offering on the NASDAQ Global Market
9. Acsis Introduces "Serialization in a Box," Enabling Pharmaceutical Companies to Achieve E-Pedigree Compliance
10. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
11. Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Denmark and ATLANTA , August ... the US Food and Drug Administration (FDA) cleared the MagVita ... in adult patients who have failed to receive satisfactory improvement ... a non-invasive technique for stimulating neural tissue in the part ... Disorder. The procedure has been proven safe and effective and ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de 2015 ... anunció hoy su participación en el  Congreso de ... soluciones cardiológicas más recientes y novedosas, entre ellas ... conectan a las personas y la tecnología con ... a diagnosticar, guiar los tratamientos y permitir atención ...
(Date:8/27/2015)...  A recent study by Feucht et al, ... Arthrosurface HemiCAP® Wave implant, which is based on ... implant for isolated patellofemoral disease. While both implant ... scores, none of the patients in the "inlay" ... of the patients in the "onlay" group, showed ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... Dec. 18 Curemark,s Board of Directors,announced today that ... the,company as a senior scientist and will serve on ... of the Department of,Pediatrics at The Long Island College ... New York Health Science Center at Brooklyn., "Dr. ...
... Inc. (Nasdaq:,INSM), a developer of follow-on biologics and ... (FDA) has granted Orphan,Drug Designation for IPLEX(TM) for ... currently conducting a 24-week Phase III,enabling trial for ... grant of,approximately $2.1 million from the Muscular Dystrophy ...
Cached Medicine Technology:Curemark Appoints Preeminent Pediatrics Gastroenterologist 2Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy 2Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy 3
(Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... 1996," said one of two inventors from Miller Place, N.Y. "I specialize in ... pain and discomfort. In addition, it can be used for additional muscle dysfunction ...
(Date:8/29/2015)... ... August 29, 2015 , ... Next weekend is Labor ... (which astronomically, officially ends on September 22nd this year). For IT security personnel, it ... linger on which could prove far more costly than a simple headache. , Joe ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced today ... and Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed. ... (VHS) in the United States District Court for the Southern District of Texas ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner ... they are applying for, they are unable to pass the initial drug test and ... testing policies in order to be able to hire long-term, skilled talent. (1) Will ...
(Date:8/28/2015)... , ... August 28, 2015 , ... As reported ... Merz, received FDA clearance for results that last for two years, the longest ... news for patients who are looking for a long-lasting, effective solution for their cellulite, ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
... DC (February 1, 2010) Through the use of ... how to teach their child to communicate and improve ... 2010 issue of The Journal of Positive Behavior ... and SAGE)., Family members play a central role in ...
... blue skies and majestic mountains provided a scenic ... the most promising technologies on the horizonnanomedicine, or ... dedicated to constructing microscopic probes and biomechanical devices. ... academic, government and industry experts from across a ...
... may someday improve prevention efforts , MONDAY, Feb. 1 (HealthDay ... a pregnant mouse leads to changes inside the uterus that ... fetus. , The findings, published online in the ... to prevent and treat premature birth, the study,s senior investigator, ...
... ... you transform the way employees engage inside and outside of the workplace. , ... Milwaukee, Wisc. (PRWEB) February 1, 2010 -- ... the Corporate and Personal Brand,” hosted by Loyola University in Chicago. The hands-on ...
... were more likely to delay having sex, , , MONDAY, ... education classes were more likely to delay having sex, a ... 6th- and 7th-grade students, ranging in age from 10 to ... held on Saturdays at four Philadelphia public schools that draw ...
... and memory skills after 12 weeks of treatment, researchers ... antidepressants after a stroke may help repair the damaged ... , Little has been shown to help the brain ... after initial stroke treatment. But a University of Iowa ...
Cached Medicine News:Health News:Distance education for parents of children with autism found effective 2Health News:Summit examines vast applications of nanomedicine 2Health News:Summit examines vast applications of nanomedicine 3Health News:7Summits to Present at Soho Seminars 'Alignment of Personal and Corporate Brands' 2Health News:Abstinence-Only Classes Reduced Sexual Activity, Study Found 2Health News:Abstinence-Only Classes Reduced Sexual Activity, Study Found 3Health News:Antidepressants After Stroke May Boost Mental Ability 2Health News:Antidepressants After Stroke May Boost Mental Ability 3
For the quantitative in vitro determination of creatinine in serum, plasma or urine....
The TBIL method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of total bilirubin in serum and plasma...
The DBIL method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of direct (conjugated) bilirubin in serum and plasma....
Latex agglutination slide test for the qualitative and semi-quantitative determination of Anti-Streptolysin O (ASO) in human serum...
Medicine Products: